Telomir Pharmaceuticals (NASDAQ:TELO) Announces Earnings Results, Beats Expectations By $0.01 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) released its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01, FiscalAI reports.

Telomir Pharmaceuticals Stock Performance

NASDAQ TELO traded up $0.01 during trading on Tuesday, hitting $1.35. The stock had a trading volume of 35,742 shares, compared to its average volume of 126,783. The company’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $1.36. The company has a market capitalization of $46.41 million, a PE ratio of -3.65 and a beta of -0.66. Telomir Pharmaceuticals has a 12 month low of $1.05 and a 12 month high of $4.81.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TELO shares. Wall Street Zen raised shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Rodman & Renshaw started coverage on Telomir Pharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Qube Research & Technologies Ltd acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $33,000. XTX Topco Ltd acquired a new stake in Telomir Pharmaceuticals during the fourth quarter worth approximately $53,000. Bank of America Corp DE increased its stake in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after acquiring an additional 10,880 shares during the period. Jane Street Group LLC acquired a new position in Telomir Pharmaceuticals in the 2nd quarter valued at $62,000. Finally, Marshall Wace LLP bought a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter valued at $95,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.